Molecular Formula | C25H27N5 |
Molar Mass | 397.52 |
Density | 1.216±0.06 g/cm3(Predicted) |
Boling Point | 620.4±65.0 °C(Predicted) |
Solubility | DMSO: soluble10mg/mL, clear |
Appearance | powder |
Color | white to beige |
pKa | 4.99±0.10(Predicted) |
Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
In vitro study | AT-56 (1-30 μM; 10 minutes) dose-dependently inhibits the production of PGD 2 in L-PGDS-expressing human medulloblastoma TE-671 cells with an IC 50 of about 3 μM. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.516 ml | 12.578 ml | 25.156 ml |
5 mM | 0.503 ml | 2.516 ml | 5.031 ml |
10 mM | 0.252 ml | 1.258 ml | 2.516 ml |
5 mM | 0.05 ml | 0.252 ml | 0.503 ml |
biological activity | AT-56 is an orally active lipocalin-type protaglandin (PG) D synthase (L-PGDS) the corresponding Ki and IC50 values were 75 μm and 95 μm, respectively. |
Target | Value |
L-PGDS (Cell-free assay) | 75 μM(Ki) 95 μM |
Animal Model: | H-PGDS KO mice (14-16weeks, 25-30 g, C57BL/6 strain) with a stab wound brain injury Human L-PGDS-overexpressing TG mice (males, 14-16 weeks, 25-30 g) Male C57BL/6 mice (7 weeks, 22-26 g) |
Dosage: | 0, 1, 3, 10, 30 mg/kg 0, 1, 10 mg/kg 10 mg/kg for p.o. and 2 mg/kg for i.v. (Pharmacokinetic Analysis) |
Administration: | P.o. 1 h before the stab wound injury P.o. 1 h before and 24 h after the antigen exposure P.o. and i.v. administration |
Result: | Inhibited the L-PGDS reaction in the brain. Decreased the total amount of PGD 2 in the brain to 40% with 30 mg/kg AT-56. Prevented the eosinophil infiltration by inhibiting transgened human L-PGDS. Oral bioavailability (82%); C max (2.15 μg/ml); T 1/2 (1.71 h, p.o.); T 1/2 (2.35 h, i.v.). |